Thomas C. Binns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas C. Binns has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Jeremy W. Jacobs
Department of Pathology, Microbiology, and Immunology Vanderbilt University Nashville Tennessee USA
5 shared publications - Christopher Anthony Tormey
Department of Laboratory Medicine Yale School of Medicine New Haven Connecticut USA
4 shared publications - Alexandra S. Piotrowski-Daspit
Department of Biomedical Engineering University of Michigan Ann Arbor USA
3 shared publications Elizabeth Abels
Department of Laboratory Medicine Yale School of Medicine New Haven Connecticut USA
3 shared publicationsNataliya Sostin
Department of Laboratory Medicine Yale School of Medicine New Haven Connecticut USA
3 shared publications- William Mark Saltzman
Yale University
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 12 (6) , 065011
Non-invasive near-infrared measurement of blood concentration in chest tube output: a proof-of-concept study
Background. Chest tube management requires assessing drainage volume and blood content, but only volume can be measured objectively at the bedside; visual estimation of blood concentration is unreliable. We developed and evaluated a low-cost near-infrared spectroscopy (NIRS) device for non-invasive measurement of blood concentration in chest tube output. Methods. An Arduino-based prototype with six light-emitting diode wavelengths (660, 740, 765, 810, 850, 940 nm), an OPT101 photodiode, and a 3D-printed enclosure was constructed. Bovine blood was diluted with normal saline into ten concentrations (0%–90%, 10% increments), with five randomized measurements per dilution ( n = 50). Single-wavelength exponential, two-wavelength composite, and six-wavelength multivariable models were fitted. Each measurement was assigned to the calibrated level for which the fitted signal lay closest to the observed value. Performance was assessed as apparent and cross-validated coefficient of determination, classification accuracy within one dilution level, and Bland–Altman agreement, with cluster bootstrap confidence intervals. Results. Within-tube coefficients of variation had a median of 15% (interquartile range 8% to 26%). The 660 nm wavelength showed the strongest relationship with blood proportion (signal-direction R 2 = 0.89). In the prediction direction, the 660 nm model achieved R 2 = 0.796 apparent and 0.741 under leave-one-tube-out cross-validation, whereas six-wavelength regression achieved the highest apparent value (0.804) but fell to 0.697 when cross-validated. Classification accuracy within one dilution level was 74% (95% CI 60%;84%) under all three evaluation schemes, and 68% for the composite. Bland–Altman analysis showed a bias of 2.0% (95% CI −2.2;4.6), with 95% limits of agreement of −23.4% to 27.4% relative to ground-truth. Conclusions. This study demonstrates the feasibility of a low-cost NIRS device for non-invasive estimation of blood concentration in chest tube output. The wide limits of agreement indicate that the device supports discrimination between low and high blood content rather than point estimation, pending validation in clinical drainage samples.
- 9 November 2026
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 12 (6) , 065011
Open AccessNon-invasive near-infrared measurement of blood concentration in chest tube output: a proof-of-concept study
Background. Chest tube management requires assessing drainage volume and blood content, but only volume can be measured objectively at the bedside; visual estimation of blood concentration is unreliable. We developed and evaluated a low-cost near-infrared spectroscopy (NIRS) device for non-invasive measurement of blood concentration in chest tube output. Methods. An Arduino-based prototype with six light-emitting diode wavelengths (660, 740, 765, 810, 850, 940 nm), an OPT101 photodiode, and a 3D-printed enclosure was constructed. Bovine blood was diluted with normal saline into ten concentrations (0%–90%, 10% increments), with five randomized measurements per dilution ( n = 50). Single-wavelength exponential, two-wavelength composite, and six-wavelength multivariable models were fitted. Each measurement was assigned to the calibrated level for which the fitted signal lay closest to the observed value. Performance was assessed as apparent and cross-validated coefficient of determination, classification accuracy within one dilution level, and Bland–Altman agreement, with cluster bootstrap confidence intervals. Results. Within-tube coefficients of variation had a median of 15% (interquartile range 8% to 26%). The 660 nm wavelength showed the strongest relationship with blood proportion (signal-direction R 2 = 0.89). In the prediction direction, the 660 nm model achieved R 2 = 0.796 apparent and 0.741 under leave-one-tube-out cross-validation, whereas six-wavelength regression achieved the highest apparent value (0.804) but fell to 0.697 when cross-validated. Classification accuracy within one dilution level was 74% (95% CI 60%;84%) under all three evaluation schemes, and 68% for the composite. Bland–Altman analysis showed a bias of 2.0% (95% CI −2.2;4.6), with 95% limits of agreement of −23.4% to 27.4% relative to ground-truth. Conclusions. This study demonstrates the feasibility of a low-cost NIRS device for non-invasive estimation of blood concentration in chest tube output. The wide limits of agreement indicate that the device supports discrimination between low and high blood content rather than point estimation, pending validation in clinical drainage samples.
- Open Access
- 2 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (18) , eadt8637
Cellular determinants influence the red blood cell adsorption efficiency of poly(amine- co -ester) nanoparticles
Many poly(amine- co -ester) (PACE) nanoparticles, drug delivery vehicles for nucleic acid and small molecule cargoes, accumulate in the liver and spleen following intravenous administration, limiting delivery to nonhepatosplenic tissues. Red blood cell (RBC) hitchhiking, a strategy in which nanoparticles are nonspecifically adsorbed to RBCs prior to administration, has been used to modulate nanoparticle biodistribution, enabling enrichment in organs immediately downstream from the site of vascular infusion. We find that scarcely investigated cellular determinants—namely, storage duration, membrane stiffness, and membrane-bound sialic acid quantity—substantially affect PACE nanoparticle adsorption efficiency. Following development of an optimized adsorption protocol, RBC hitchhiking was shown to enhance PACE nanoparticle cargo delivery to pulmonary tissue while also increasing exposure to other assayed organs. These findings inform future RBC hitchhiking study design, implicate cellular variables as potential obstacles or boons to clinical translation, and demonstrate the delivery of nucleic acids using this strategy with the PACE nanoparticle platform.
- 2 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (18) , eadt8637
Open AccessCellular determinants influence the red blood cell adsorption efficiency of poly(amine- co -ester) nanoparticles
Many poly(amine- co -ester) (PACE) nanoparticles, drug delivery vehicles for nucleic acid and small molecule cargoes, accumulate in the liver and spleen following intravenous administration, limiting delivery to nonhepatosplenic tissues. Red blood cell (RBC) hitchhiking, a strategy in which nanoparticles are nonspecifically adsorbed to RBCs prior to administration, has been used to modulate nanoparticle biodistribution, enabling enrichment in organs immediately downstream from the site of vascular infusion. We find that scarcely investigated cellular determinants—namely, storage duration, membrane stiffness, and membrane-bound sialic acid quantity—substantially affect PACE nanoparticle adsorption efficiency. Following development of an optimized adsorption protocol, RBC hitchhiking was shown to enhance PACE nanoparticle cargo delivery to pulmonary tissue while also increasing exposure to other assayed organs. These findings inform future RBC hitchhiking study design, implicate cellular variables as potential obstacles or boons to clinical translation, and demonstrate the delivery of nucleic acids using this strategy with the PACE nanoparticle platform.
- 17 April 2025
- Published by Wiley in Transfusion
- Vol. 65 (4) , 785-787
Intravenous immune globulin and risk factors for adverse events in the pediatric population: Considering ABO and secretor status
- 17 April 2025
- Published by Wiley in Transfusion
- Vol. 65 (4) , 785-787
Intravenous immune globulin and risk factors for adverse events in the pediatric population: Considering ABO and secretor status
- Open Access
- 26 September 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (12) , 2351-2366
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.
- 26 September 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (12) , 2351-2366
Open AccessCurrent state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.
- 22 July 2024
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 56 (1) , 85-88
Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma
Hyperviscosity syndrome (HVS) is defined as the symptomatic presentation of increased blood thickness due to various clinical conditions such as hypergammaglobulinemia. HVS secondary to immunoglobulin (Ig)A multiple myeloma has been infrequently reported. Although the efficiency of IgM or IgG removal by therapeutic plasma exchange (TPE) is well described, the efficiency of IgA removal by TPE is not as well known. Here, we describe a case of HVS due to IgA myeloma in a patient who received 2 TPE treatments, with subsequent symptomatic improvement as well as decrease in IgA and viscosity levels.
- 22 July 2024
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 56 (1) , 85-88
Therapeutic plasma exchange for hyperviscosity syndrome in IgA multiple myeloma
Hyperviscosity syndrome (HVS) is defined as the symptomatic presentation of increased blood thickness due to various clinical conditions such as hypergammaglobulinemia. HVS secondary to immunoglobulin (Ig)A multiple myeloma has been infrequently reported. Although the efficiency of IgM or IgG removal by therapeutic plasma exchange (TPE) is well described, the efficiency of IgA removal by TPE is not as well known. Here, we describe a case of HVS due to IgA myeloma in a patient who received 2 TPE treatments, with subsequent symptomatic improvement as well as decrease in IgA and viscosity levels.
- Open Access
- 18 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys
The in vivo efficacy of polymeric nanoparticles (NPs) is dependent on their pharmacokinetics, including time in circulation and tissue tropism. Here we explore the structure-function relationships guiding physiological fate of a library of poly(amine-co-ester) (PACE) NPs with different compositions and surface properties. We find that circulation half-life as well as tissue and cell-type tropism is dependent on polymer chemistry, vehicle characteristics, dosing, and strategic co-administration of distribution modifiers, suggesting that physiological fate can be optimized by adjusting these parameters. Our high-throughput quantitative microscopy-based platform to measure the concentration of nanomedicines in the blood combined with detailed biodistribution assessments and pharmacokinetic modeling provides valuable insight into the dynamic in vivo behavior of these polymer NPs. Our results suggest that PACE NPs—and perhaps other NPs—can be designed with tunable properties to achieve desired tissue tropism for the in vivo delivery of nucleic acid therapeutics. These findings can guide the rational design of more effective nucleic acid delivery vehicles for in vivo applications.
- 18 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessEnhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys
The in vivo efficacy of polymeric nanoparticles (NPs) is dependent on their pharmacokinetics, including time in circulation and tissue tropism. Here we explore the structure-function relationships guiding physiological fate of a library of poly(amine-co-ester) (PACE) NPs with different compositions and surface properties. We find that circulation half-life as well as tissue and cell-type tropism is dependent on polymer chemistry, vehicle characteristics, dosing, and strategic co-administration of distribution modifiers, suggesting that physiological fate can be optimized by adjusting these parameters. Our high-throughput quantitative microscopy-based platform to measure the concentration of nanomedicines in the blood combined with detailed biodistribution assessments and pharmacokinetic modeling provides valuable insight into the dynamic in vivo behavior of these polymer NPs. Our results suggest that PACE NPs—and perhaps other NPs—can be designed with tunable properties to achieve desired tissue tropism for the in vivo delivery of nucleic acid therapeutics. These findings can guide the rational design of more effective nucleic acid delivery vehicles for in vivo applications.
- 14 September 2023
- Published by Wiley in Transfusion
- Vol. 63 (11) , 2188-2196
Passive transfer of alloantibodies through breast milk as a mediator of hemolytic anemia
Background: Hemolytic disease of the fetus and newborn (HDFN) is characterized by destruction of fetal/neonatal red blood cells (RBCs) secondary to maternally derived antibodies, which are typically thought to be passively acquired via placental transfer. Few cases have examined the possibility of HDFN mediated by maternal antibodies passively transferred via breast milk.Methods: We describe two cases of persistent HDFN in infants potentially mediated by passively acquired antibodies via maternal breast milk. We discuss supporting and refuting evidence that may account for this possibility and describe testing methodology illustrating how maternal alloantibodies can be detected in breast milk.Results: In both cases, anti‐D antibodies were detected in maternal breast milk. One patient experienced a significant decrease in anti‐D plasma titer from 64 to 4 dilutions following 2 weeks of breastfeeding cessation. The other patient experienced a resolution of anemia without breastfeeding cessation.Conclusion: There is a paucity of data regarding the lifespan of passively acquired RBC antibodies in neonatal circulation, with significant variation noted between passively acquired IgG based on studies utilizing intravenous immunoglobulin compared to studies of maternally‐acquired antiviral IgG antibodies. While our data do not definitively implicate passive transfer of alloantibodies in breast milk as a mediator of HDFN, they do illustrate the need for further investigation into the mechanisms and kinetics of passively acquired antibodies in neonatal circulation.
- 14 September 2023
- Published by Wiley in Transfusion
- Vol. 63 (11) , 2188-2196
Passive transfer of alloantibodies through breast milk as a mediator of hemolytic anemia
Background: Hemolytic disease of the fetus and newborn (HDFN) is characterized by destruction of fetal/neonatal red blood cells (RBCs) secondary to maternally derived antibodies, which are typically thought to be passively acquired via placental transfer. Few cases have examined the possibility of HDFN mediated by maternal antibodies passively transferred via breast milk.Methods: We describe two cases of persistent HDFN in infants potentially mediated by passively acquired antibodies via maternal breast milk. We discuss supporting and refuting evidence that may account for this possibility and describe testing methodology illustrating how maternal alloantibodies can be detected in breast milk.Results: In both cases, anti‐D antibodies were detected in maternal breast milk. One patient experienced a significant decrease in anti‐D plasma titer from 64 to 4 dilutions following 2 weeks of breastfeeding cessation. The other patient experienced a resolution of anemia without breastfeeding cessation.Conclusion: There is a paucity of data regarding the lifespan of passively acquired RBC antibodies in neonatal circulation, with significant variation noted between passively acquired IgG based on studies utilizing intravenous immunoglobulin compared to studies of maternally‐acquired antiviral IgG antibodies. While our data do not definitively implicate passive transfer of alloantibodies in breast milk as a mediator of HDFN, they do illustrate the need for further investigation into the mechanisms and kinetics of passively acquired antibodies in neonatal circulation.
- 20 March 2023
- Published by Wiley in Transfusion
- Vol. 63 (3) , 656-657
Rh alloimmunization following transfusion of one apheresis platelet unit
- 20 March 2023
- Published by Wiley in Transfusion
- Vol. 63 (3) , 656-657
Rh alloimmunization following transfusion of one apheresis platelet unit
- 17 January 2023
- Published by Wiley in Transfusion
- Vol. 63 (4) , 872-876
Warm autoimmune hemolytic anemia with anti‐Jka specificity following babesiosis masquerading as a delayed hemolytic transfusion reaction
Background: Warm autoimmune hemolytic anemia (WAIHA) is characterized by the development of autoantibodies that react with red blood cells (RBCs) optimally at physiologic temperature, classically resulting in a positive direct antiglobulin test (DAT) for IgG and a panreactive eluate. Babesiosis has been described as a potentiator of WAIHA, and all cases have shown classic blood bank findings. Only rare reports have described autoantibodies, both secondary to babesiosis and overall, with specificity for Kidd antigens. Methods: Antibody detection and identification were performed using IgG-specific column agglutination technology. Jka antigen phenotyping was assessed using monoclonal reagents and genotypic analysis was performed at an immunohematology reference laboratory. DATs were performed via standard tube methods. The elution was performed using the ELUclear glycine acid red cell elution kit. Results: We report a case of WAIHA induced by Babesia microti infection with an autoantibody with Jka specificity, originally believed to be a delayed hemolytic transfusion reaction, given the detection of an RBC antibody in close proximity to numerous RBC transfusions. Determination of autoantibody status with anti-Jka-like reactivity was only confirmed after Kidd antigen geno-typing predicted expression of the Jka antigen. Discussion: Healthcare providers should be cognizant of the potential for babesiosis-induced WAIHA, particularly in individuals who continue to hemolyze despite undetectable parasitemia. Furthermore, this case highlights the possibility for warm autoantibodies to demonstrate Kidd antigen specificity. Though Kidd antigen variants are rare, antigen genotyping may be beneficial, particularly in the context of recent RBC transfusions, which typically preclude accurate serological phenotypic assessment.
- 17 January 2023
- Published by Wiley in Transfusion
- Vol. 63 (4) , 872-876
Warm autoimmune hemolytic anemia with anti‐Jka specificity following babesiosis masquerading as a delayed hemolytic transfusion reaction
Background: Warm autoimmune hemolytic anemia (WAIHA) is characterized by the development of autoantibodies that react with red blood cells (RBCs) optimally at physiologic temperature, classically resulting in a positive direct antiglobulin test (DAT) for IgG and a panreactive eluate. Babesiosis has been described as a potentiator of WAIHA, and all cases have shown classic blood bank findings. Only rare reports have described autoantibodies, both secondary to babesiosis and overall, with specificity for Kidd antigens. Methods: Antibody detection and identification were performed using IgG-specific column agglutination technology. Jka antigen phenotyping was assessed using monoclonal reagents and genotypic analysis was performed at an immunohematology reference laboratory. DATs were performed via standard tube methods. The elution was performed using the ELUclear glycine acid red cell elution kit. Results: We report a case of WAIHA induced by Babesia microti infection with an autoantibody with Jka specificity, originally believed to be a delayed hemolytic transfusion reaction, given the detection of an RBC antibody in close proximity to numerous RBC transfusions. Determination of autoantibody status with anti-Jka-like reactivity was only confirmed after Kidd antigen geno-typing predicted expression of the Jka antigen. Discussion: Healthcare providers should be cognizant of the potential for babesiosis-induced WAIHA, particularly in individuals who continue to hemolyze despite undetectable parasitemia. Furthermore, this case highlights the possibility for warm autoantibodies to demonstrate Kidd antigen specificity. Though Kidd antigen variants are rare, antigen genotyping may be beneficial, particularly in the context of recent RBC transfusions, which typically preclude accurate serological phenotypic assessment.
- 20 December 2022
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 37 (1) , 16-20
State of the Evidence: Drug Removal via Apheresis
- 20 December 2022
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 37 (1) , 16-20
State of the Evidence: Drug Removal via Apheresis